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Introduction: Improving the surveillance of tuberculo-
sis (TB) is especially important for multidrug-resistant 
(MDR) and extensively drug-resistant (XDR) TB. The 
large amount of publicly available whole genome 
sequencing (WGS) data for TB gives us the chance to 
re-use data and to perform additional analyses at a 
large scale. Aim: We assessed the usefulness of raw 
WGS data of global MDR/XDR  Mycobacterium tuber-
culosis  isolates available from public repositories to 
improve TB surveillance. Methods: We extracted raw 
WGS data and the related metadata of  M. tuberculo-
sis isolates available from the Sequence Read Archive. 
We compared this public dataset with WGS data and 
metadata of 131 MDR- and XDR  M. tuberculosis  iso-
lates from Germany in 2012 and 2013. Results: We 
aggregated a dataset that included 1,081 MDR and 250 
XDR isolates among which we identified 133 molecu-
lar clusters. In 16 clusters, the isolates were from at 
least two different countries. For example, Cluster  2 
included 56 MDR/XDR isolates from Moldova, Georgia 
and Germany. When comparing the WGS data from 
Germany with the public dataset, we found that 11 clus-
ters contained at least one isolate from Germany and 
at least one isolate from another country. We could, 
therefore, connect TB cases despite missing epidemio-
logical information. Conclusion: We demonstrated the 
added value of using WGS raw data from public reposi-
tories to contribute to TB surveillance. Comparing the 
German with the public dataset, we identified poten-
tial international transmission events. Thus, using this 
approach might support the interpretation of national 
surveillance results in an international context.
Introduction
Improving the surveillance of tuberculosis (TB) is one of 
the eight core activities identified by the World Health 
Organization (WHO) and the European Respiratory 
Society to achieve TB elimination, defined as less than 
one incident case per million [1]. Monitoring transmis-
sion is especially important for multidrug-resistant 
(MDR)  Mycobacterium tuberculosis  isolates – defined 
as being resistant to rifampicin and isoniazid – and 
for extensively drug-resistant (XDR)  M. tuberculo-
sis  isolates – defined as MDR isolates with additional 
resistance to at least one of the fluoroquinolones and 
at least one of the second-line injectable drugs. In 
2017, the WHO estimated that worldwide more than 
450,000 people fell ill with MDR-TB and among these, 
more than 38,000 fell ill with XDR-TB [2].
The rapid advance in molecular typing technology – 
especially the availability of whole genome sequencing 
(WGS) to identify and characterise pathogens – gives 
us the chance to integrate this information into dis-
ease surveillance. For TB surveillance, it is possible 
to combine the results of molecular typing of isolates 
from the  M. tuberculosis  complex with traditional 
epidemiological information to infer or to exclude TB 
transmission [3,4]. This is of particular relevance if 
transmission occurs among multiple countries, where 
epidemiological data such as social contacts are more 
difficult to get and where data exchange is more dif-
ficult to organise. The European Centre for Disease 
Prevention and Control (ECDC) reported 44 events 
of international transmission (international clusters) 
of MDR-TB in different European countries between 
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2012 and 2015 [5]. In that report, the authors inferred 
TB transmission using the mycobacterial interspersed 
repetitive units variable number of tandem repeats 
(MIRU-VNTR) typing method. However, this method has 
limitations such as low correlation with epidemiologi-
cal information in outbreak settings and low discrimi-
natory power [3,6]. In comparison, WGS analysis offers 
a much higher discriminatory power and allows infer-
ring (or excluding) TB transmission at a higher resolu-
tion [4]. In a recent systematic review, van der Werf et 
al. identified three studies that used WGS to investi-
gate the international transmission of TB [7].
In recent years, the amount of available WGS data is 
increasing, especially because sequencing has become 
cheaper [8]. In addition, more and more authors deposit 
the raw data of their projects in open access public 
repositories such as the Sequence Read Archive (SRA) 
of the National Center for Biotechnology Information 
(NCBI) [9]. These publicly available raw WGS data 
for thousands of isolates enable the re-use and the 
additional analyses at a large and global scale [10]. For 
example, it is possible to compare genomic data among 
different studies or countries since the data are availa-
ble in a single place. Moreover, new software tools can 
be tested using the same raw WGS data [11]. However, 
standards in bioinformatics analysis and interpretation 
of these WGS data for surveillance purposes are not yet 
fully established [12].
We aimed to assess the usefulness of raw WGS data 
of global MDR/XDR  M. tuberculosis  isolates available 
in public repositories to improve TB surveillance. 
Specifically, we wanted to identify potential 
international events of TB transmission and to compare 
the international isolates with a collection of M. tuber-
culosis isolates collected in Germany in 2012 and 2013.
Figure 1
Flowchart of the inclusion and exclusion of Mycobacterium tuberculosis isolates in our study from the public and the 
German dataset, 1996–2016a (n = 9,256)
Public dataset
9,112 
































MDR: multidrug-resistant; XDR: extensively drug-resistant.
The final dataset included 1,335 isolates: 1,204 from the public and 131 from the German dataset.
a The isolates from the German dataset covered the period 2012–13.
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Methods
Data collection: public dataset
The SRA database is a public repository provided by 
the NCBI National Library of Medicine, Bethesda, 
United States (US) which stores raw sequencing data 
derived from high-throughput sequencing platforms 
[9]. We queried the repository (last access: 1 March 
2019) for the pathogen ‘Mycobacterium tuberculosis’ 
with samples isolated between 1996 and 2016 and 
restricted the results to ‘genomic’, ‘WGS’ data from the 
‘Illumina’ sequencing technology using the appropriate 
query keywords. After excluding single end-sequenced 
and missing raw data, 8,716 isolates remained, which 
were further filtered for sequence characteristics. We 
excluded samples with reads shorter than 100 bp as 
well as samples with a low (< 20 ×) or high (> 500 ×) 
average coverage depth of the reference genome (see 
below) to obtain a more homogenous dataset. In addi-
tion, we excluded samples with less than 90% reads 
aligned to the reference genome to prevent having 
contaminated or incorrectly annotated samples in the 
set. We also excluded samples for which more than 
50% of all detected single-nucleotide variants were 
inconclusive (see  Supplementary Material  for details). 
To identify duplicates (e.g. the same file uploaded 
more than once in different projects) within the public 
dataset, we compared numbers of reads and detected 
variants at every step of the analysis. We excluded 
duplicate samples that were identical in all those 
numbers and their corresponding epidemiological data. 
After all filtering steps, 7,620 isolates remained and 
we will refer to these isolates as the ‘public dataset’ 
throughout the manuscript. In addition to the raw 
reads, we also collected metadata available in the SRA 
repository [9] (for details see Supplementary Table S1).
Data collection: German dataset
In addition to the international public dataset, we ana-
lysed isolates from Germany, which will be referred to 
as ‘German dataset’ throughout the manuscript. The 
German dataset included all  M. tuberculosis  complex 
isolates processed at the National Reference Center for 
Mycobacteria (Forschungszentrum Borstel, Germany) 
and classified as MDR-TB or XDR-TB in 2012 and 2013 by 
drug susceptibility tests (DST) according to the German 
TB surveillance system [13]. We chose 2012 and 2013 
because for those two years, we had all correspond-
ing epidemiological metadata, which are not available 
from the German TB surveillance system by default. We 
extracted the epidemiological data available for these 
isolates using the laboratory identification number of 
the National Reference Center for Mycobacteria. Then, 
we identified the respective isolate in the national 
surveillance system at the Robert Koch Institute (the 
German public health institute) and matched molecular 
with epidemiological data. We collected information on 
year of isolation, federal state of isolation, DST results, 
and patient-related information such as age, sex, citi-
zenship and country of birth.
Table 1
Characteristics of multi- and extensively drug-
resistant Mycobacterium tuberculosis isolates from 












































a E.g. bronchoalveolar lavage, lymph node.
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Whole genome sequencing analysis workflow
Raw reads were subjected to quality control with 
Trimmomatic [14] and Flash [15]. The trimmed and 
filtered reads were mapped to two different refer-
ence genomes: the  M. tuberculosis  H37Rv strain and 
a pan-genome reference built from 146  M. tuberculo-
sis  genomes [16,17] with Burrow–Wheeler algorithm 
bwa-mem [18]. Duplicated reads were marked and 
reads with mapping quality less than 10 were excluded. 
The Genome Analysis Toolkit (GATK) [19] was used to 
detect variants mapped to both reference genomes and 
to extract all SNPs of high quality (see Supplementary 
Material for details).
Drug-resistance prediction
We used Phyresse [20] and TBDreamDB [21] to identify 
drug resistance mutations in our datasets (last access: 
18 October 2018). We filtered both lists to include 
only single nucleotide substitutions. For TBDreamDB, 
we mapped the provided locations within resist-
ance genes to positions on the  M. tuberculosis  H37Rv 
genome where necessary. We excluded mutations not 
associated with drug resistance according to the WHO 
[22] and to the CRyPTIC study [23] (see Supplementary 
Table S2  for the list of all identified mutations and, 
among those, all the excluded mutations). For each 
sample, we intersected the variants detected by read 
mapping to the  M. tuberculosis  H37Rv genome with 
this list of known mutations to identify resistance-
associated mutations. We also identified uncovered or 
low-quality regions that overlapped with locations of 
resistance mutations. For the classification of isolates 
into resistance classes (MDR-TB and XDR-TB), we used 
the definitions of the WHO [2].
Molecular clustering
We used PANPASCO [17] to calculate relative pair-
wise single nucleotide polymorphism (SNP) distance 
between all isolates classified as MDR-TB or XDR-TB 
in the public and German dataset. This method builds 
on two parts to enable distance calculation for large, 
diverse datasets: mapping all reads to a computational 
pan-genome including 146  M. tuberculosis  genomes 
and distance calculation for each individual pair of 
samples. For this, we identified all positions with high 
quality for each pair of samples and calculated the SNP 
distance based on this set of positions (for details on 
the filtering workflow, PANPASCO and distance calcula-
tion see  Supplementary Material). SNPs in repeat-rich 
genes were not used for distance calculations as stud-
ies have shown that variants found in these regions are 
often false positives [3,24]. The list of genes provided 
by Comas et al. was used for filtering [25].
We applied single-linkage agglomerative clustering for 
defining transmission clusters and used a threshold of 
fewer than 13 SNPs, based on a previous study [26]. 
We chose the threshold of 13 SNPs (or ≥ 13 SNPs) as 
cluster exclusion criteria because we aimed to identify 
larger events of international transmission of TB, in 
contrast to a threshold of 6 SNPs (or  ≥ 6 SNPs), which 
Table 2
Characteristics of multidrug- and extensively drug-
resistant Mycobacterium tuberculosis isolates analysed in 
this study, Germany, 2012–2013 (n = 131)
Characteristic n

























































MDR: multidrug-resistant; XDR: extensively drug-resistant; NA: not 
available.
We found demographic information, epidemiological information 
and drug susceptibility test results in the German tuberculosis 
surveillance system for 129 of 131 isolates.
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might be more useful to identify recent transmission of 
TB [27,28]. Besides, we chose the threshold of 13 SNPs 
because our isolates were spread in terms of location 
and time (see below) and because we were probably 
missing several intermediary isolates (and cases) in 
our collection. PANPASCO calculates distances based 
on data available for each pair separately. For this rea-
son, an individual sample can potentially have small 
distances to samples that have a much greater dis-
tance in direct comparison, owing to a higher number of 
compared high-quality sites. In this study, we aimed to 
discover clusters of closely related samples. Therefore, 
the implemented agglomerative clustering approach 
evaluated the distance from the sample that should be 
added to two instead of one sample of an existing clus-
ter – we compared not only pairs of samples but two 
sets of trios. The sample was added to the cluster only 
if the maximum distance in the trio was below twice 
the SNP threshold. Samples that violated this condition 
Figure 2
Visualisation of the transmission Cluster 2 identified among the Mycobacterium tuberculosis isolates analysed in our study, 




























































The country of isolation, multi- and extensive drug-resistance classification and year of isolation are represented in the clusters. SNP 
distances were calculated for each pair of isolates individually. Links with fewer than 6 SNPs are marked black, those with fewer than 13 
SNPs are marked in grey. Connections with 13 SNPs or more than are not shown in the network.
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were iteratively removed from the clustering and were 
marked for potential follow-up analyses.
We used Cytoscape 3.7 to visualise the clusters [29]. 
We classified all clustered samples into TB lineages 
using lineage-specific SNPs provided in [30] and [31] 
(see Supplementary Table S6). We compared and vali-
dated clustering results of a subset of isolates using 
the pipeline MTBSeq [32] (see  Supplementary Table 
S7).
Data availability
The raw WGS data used in this study are available 
in the NCBI SRA repository. The accession numbers 
for all samples of the public dataset are available 
in Supplementary Table S1. The German dataset is avail-
able as Bioproject PRJEB35201. Software for creating 
a pan-genome sequence (seq-seq-pan) is accessible 
at  https://gitlab.com/rki_bioinformatics/seq-seq-pan, 
and scripts for the NGS workflow and the SNP-distance 
method (PANPASCO) are available at  https://gitlab.
com/rki_bioinformatics/panpasco. The code for the 
clustering method is available at  https://gitlab.com/
rki_bioinformatics/snp_distance_clustering.
Ethical statement
Ethical approval was not required for this study since 
data were extracted from pseudonymised notification 
data.
Table 3
Characteristics of the 11 molecular clusters identified in this study which contain at least one isolate from Germany and at 
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0 0 Georgia (1) Georgia (1)
MDR: multidrug-resistant; XDR: extensively drug-resistant; NA: not available.
In bold the isolates from Germany. Within each cluster, information about the country of birth and nationality of the patient are provided.




After the filtering steps, 7,620 of initially 8,716 down-
loaded isolates remained in the public dataset and 131 
isolates in the German dataset (Figure 1). We focused 
our study on MDR/XDR-TB, and therefore the final 
dataset contained overall 1,335 isolates after filter-
ing using resistance-associated SNPs.  Supplementary 
Table S1 shows the cluster assignment, molecular drug 
resistance prediction and extracted metadata of these 
1,335 isolates. 
Metadata availability and drug-resistance 
prediction: public dataset (n = 1,204)
The majority of metadata collected from the public data-
set consisted of the country of isolation (1,049/1,204; 
87.13%), the year of isolation (921/1,204; 76.50%) 
and the sample type (997/1,204; 82.81%) (Table 1). 
For other metadata, we could collect less informa-
tion, for example for patient age (174/1,204; 14.45%), 
patient sex (171/1,204; 14.20%), or patient HIV status 
(157/1,204; 13.04%) (Supplementary Table S1). For 912 
isolates, we had information on both country and year 
of isolation. Initially, we identified 336 isolates with 
missing data for the country of isolation. After examin-
ing the Bioproject information (SRA [9]) for these 336 
isolates, we could identify the country of isolation for a 
further 177 isolates, leaving us with 155 isolates with-
out any information regarding the country of isolation. 
We identified 970 MDR (80.56%) and 234 XDR (19.44%) 
isolates.
Metadata availability and drug resistance 
prediction: German dataset (n = 131)
We could retrieve demographics, epidemiological 
information and DST results for 129 of 131 (98.47%) 
of the isolates from the German TB surveillance sys-
tem. Characteristics of the molecular clusters for the 
German data set are shown in Table 2. Supplementary 
Table S3 shows the corresponding collected metadata 
for the public data set. The 131 German isolates 
came from 15 of the 16 German federal states. The 
most frequent countries of birth of the patients were 
Russia (27/131; 20.61%), Germany (19/131; 14.50%) and 
Romania (10/131; 7.63%) (Table 2).
We noted discrepancies in the identification of 
rifampicin resistance between the results of the phe-
notypic DST and the detection of drug resistance muta-
tions in 13 isolates (documented in  Supplementary 
Table S3). Specifically, four isolates were classified 
as MDR in the TB surveillance system while they 
were classified as non-MDR according to the molecu-
lar analysis because they did not contain any known 
drug resistance mutations against rifampicin. However, 
in one of these four isolates we found insufficient 
sequencing coverage in some of the genomic regions 
with known resistance mutations for rifampicin; while 
in another isolate we found an insertion of 3 nt near a 
region with known resistance mutations for rifampicin. 
In addition, nine isolates were classified as MDR in the 
TB surveillance system, while they were classified as 
XDR according to the analysis of the drug resistance 
mutations. The reason for such discrepancy was that a 
drug resistance mutation against amikacin, kanamycin 
or capreomycin was identified in these 10 isolates, but 
no DST results were available for these antibiotics.
Molecular clustering and comparison between 
the public and the German dataset
Among all isolates of our study, we identified 133 
molecular clusters (with at least two isolates) and 
591 singletons. The 133 clusters included 744 iso-
lates (Supplementary Table S4).  Supplementary Table 
S5 shows a summary of distances between all isolates 
for all molecular clusters. In 16 clusters, the isolates 
were from at least two different countries of isolation, 
suggesting larger events of international transmission 
of TB (Supplementary Table S4). For example, Cluster 2 
included 56 MDR/XDR isolates collected in three coun-
tries – Georgia (n = 1), Germany (n = 2) and Moldova 
(n = 50), including three samples without information 
on country of collection. A total of 51 of the 56 isolates 
in this cluster were part of a previous study (Bioproject 
PRJNA318002 [33],  Supplementary Table S1). In  Figure 
2  we show the country of isolation and the year of 
isolation of the isolates belonging to Cluster 2. 
Cluster  1 was the largest cluster (n = 79) identified in 
our study. According to the metadata such as host 
subject (the patient identification number), isolate 
name, year of isolation, patient age, and patient sex 
(see  Supplementary Table S1), the isolates were 79 
autopsy samples from different anatomic sites (such 
as lung or liver) of the same patient, marked as P21. 
Similarly, Cluster  3, Cluster  14, Cluster  16, Cluster  18 
and Cluster 28 contained multiple isolates from single 
patients from South Africa, which were part of a study 
including 2,693 autopsy samples of 44 subjects [34]. 
In line with previous findings [34], our analysis showed 
very low variability within the South African clusters, 
highlighted by the low maximum cluster distances in 
each of these ‘single-patient’ clusters (Supplementary 
Table S5). Also, Cluster  26, Cluster  32 and Cluster  33 
included multiple isolates from single patients. These 
isolates were part of a study investigating the evolu-
tion of drug-resistant TB in patients during long-term 
treatment [35].
When we compared the German dataset with the public 
dataset, we observed that in 11 clusters, there was at 
least one isolate from Germany and at least one iso-
late from another country.  Table 3  shows the relation 
between the German isolates and the international 
isolates from the public dataset. The epidemiological 
information collected from the German isolates 
correlates well with molecular clusters in seven of 11 
cases. For example in Cluster 9, there were 16 isolates 
from Georgia and two isolates from Germany; the 
country of birth recorded for one of the two patients 
from Germany was Georgia. Also Cluster 24, Cluster 35 
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and Cluster  103 included isolates from Georgia and 
Germany, and the country of birth recorded for the 
patients from Germany was Georgia. Three further 
examples of agreement between molecular and 
epidemiological data were: Cluster  13 which included 
isolates from Germany and Kazakhstan, Cluster  53 
which included isolates from Germany and from 
Romania, and Cluster 58 which included isolates from 
Germany and India (Table 3). By comparing the molecu-
lar data of the German and the public dataset, we could 
connect cases that had previously not been epidemio-
logically linked. For example in Cluster  2 (Figure 2), 
two isolates from Germany (in orange) were connected 
through several isolates from Georgia and Moldova 
(in dark and light blue), and the distance between the 
two German isolates was ≥ 13 SNPs. Similarly, in the 
Cluster 53, two isolates from Romania were connected 
through a German isolate, and the distance between 
the two isolates from Romania was ≥ 13 SNPs (data not 
shown). 
Discussion
In this study, we assessed whether raw WGS data of 
MDR-/XDR  M. tuberculosis  isolates available from 
public sequence repositories are useful to improve TB 
surveillance. We identified several molecular clusters 
including isolates from multiple countries, suggesting 
larger events of international transmission of TB. We 
expected to find international TB transmission events, 
also considering previous studies reporting cross-
border molecular clusters [5,7]. Looking at the collected 
metadata, we identified several clusters with multiple 
isolates from the same patient or multiple autopsy 
samples collected from the same patient [34,35]. This 
shows the importance of providing complete metadata 
together with the publicly available molecular data. 
Based on the metadata, we could distinguish between 
clusters of isolates taken from different patients – the 
real transmission clusters – and clusters of isolates 
taken from a single patient. The real transmission clus-
ters are crucial for the routine TB surveillance, while 
the clusters of isolates taken from the same patient are 
useful to study the intra-host variability of isolates.
We observed agreement between molecular and epi-
demiological data by comparing the public and the 
German datasets. This is clear for example in the clus-
ters originating from Georgia, which contained isolates 
from both the German dataset and the public dataset. It 
is therefore likely that migrants from Georgia acquired 
the TB infections in their home country – or during vis-
its there – and were diagnosed later when they moved 
or returned to Germany, as already described [36]. 
This shows that we could identify events of potential 
international transmission (between Germany and 
Georgia) that we could have missed by looking only at 
the German molecular clusters. Our analysis can have 
implications for surveillance and public health, for 
example by linking TB patients from different countries 
during contact tracing procedures. In the best scenario, 
where we could compare the German and the public 
dataset in (almost) real time, we would detect interna-
tional transmission of TB earlier and inform the public 
health authorities timely.
We observed discrepancies in the identification of 
rifampicin resistance between the phenotypic DST and 
the detected drug resistance mutations. Specifically, 
four isolates were phenotypically resistant to rifampicin 
but they did not contain any known drug resistance 
mutations against rifampicin or the genetic regions 
containing the known mutation had lower sequenc-
ing quality. This means that in our study, the known 
drug resistance mutations (there might be always new 
mutations conferring resistance) correctly predicted 
the resistance to rifampicin in 125 of 129 isolates, 
resulting in a sensitivity of 96.9%. This sensitivity is 
in accordance with a study by the CRyPTIC Consortium, 
where the authors reported a sensitivity of 97.5% [23]. 
Misclassification occurred in four isolates, which were 
MDR by phenotype, but non-MDR by genotype. This 
might have had consequences for patient therapy if we 
had replaced the phenotypic DST with the molecular 
detection of drug resistance mutations. Therefore, we 
suggest being careful in the transition from phenotypic 
to genotypic drug resistance determination as sug-
gested by the CRyPTIC Consortium [23]. Specifically, 
laboratories and national reference laboratories should 
still perform the phenotypic DST, for example on a rep-
resentative set of isolates or isolates with low sequenc-
ing quality and coverage.
Our study has three major limitations: firstly, the raw 
WGS data uploaded in the SRA repository [9] were 
either from single studies or from outbreaks and there-
fore, they were not representative of the TB situation 
in the different countries. Besides, we are probably 
missing several intermediary isolates (and cases) in 
our collection. These examples of sampling biases are, 
however, well-known biases in molecular epidemiology 
studies [37]. Secondly, the collected metadata were 
incomplete, especially regarding patient information. 
Both limitations can be overcome by genotyping all TB 
isolates, by including the genotyping results in the TB 
surveillance systems and by making genotyping data 
publicly available. Thirdly, we relied on single-linkage 
clustering, as this is currently a widely used approach 
for transmission cluster detection [38]. However, with 
many missing samples (which is probably the case 
when using a public repository), single-linkage can 
become unreliable and results strongly dependent on 
the cut-off and sample coverage for the specific cluster. 
For our study and its exploratory purpose, we preferred 
to use a widely accepted cluster detection approach 
combined with a higher cut-off. Therefore, we preferred 
to err on the side of caution (identifying a false positive 
connection) rather than miss a potential transmission. 
Thus, in future studies, researchers should carefully 
evaluate the clustering methods for transmission clus-
ter detection with missing data.
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Conclusion
Our study has one major implication: we demonstrated 
that by considering the international context (the pub-
lic dataset), while analysing the national molecular 
data (the German dataset), we could identify previ-
ously unknown transmissions between patients. Thus, 
we could detect larger and international events of TB 
transmission. To improve the WGS-based TB surveil-
lance we therefore suggest to regularly compare the 
national molecular clusters with the international 
molecular clusters available in the public sequence 
repositories. Lastly, supranational institutions such as 
the WHO, the ECDC or international TB networks could 
perform such analyses at a global scale, improving the 
global surveillance of TB.
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